bioecon Member area
Technology · Health & biomedicine / Regenerative & personalized medicine

Intact Patient-Tumor Ex-Vivo Drug Testing

Microfluidic ex vivo diagnostic platforms sustaining living, intact patient tumor fragments with intact native extracellular stroma and infiltrating immune cells, delivering actionable chemotherapy and immunotherapy sensitivity profiles within 48-72 hours.

1 · What it gives

Intact Patient-Tumor Ex-Vivo Drug Testing represents a revolutionary paradigm shift in translational pharmacology, disease modeling, and preclinical safety testing, bridging the stark translational divide between static two-dimensional cell monolayers and animal models. By reconstituting three-dimensional cellular architectures, tissue-tissue interfaces, and dynamic continuous fluidic shear in microengineered polydimethylsiloxane (PDMS) or cyclic olefin copolymer (COC) chips, the technology captures human-relevant organotypic physiology. These microphysiological systems (MPS) replicate organ-level multicellular communication, barrier integrity, and metabolic biotransformation.

The industrial platform integrates patient-derived stem or primary cells (adult stem cells or induced pluripotent stem cells iPSCs), extracellular matrix hydrogel scaffolding (such as Matrigel or synthetic hydrogels), and automated microfluidic actuation. Multi-organ microfluidic networks establish physiological vascular flow, mechanical cyclic strain (e.g., breathing lung-on-chip), and in-line transepithelial electrical resistance (TEER) barrier assessment. Analytical screening leverages confocal high-content imaging (HCS), secretome mass spectrometry, and single-cell RNA sequencing to quantify compound efficacy, pharmacokinetic-pharmacodynamic (PK/PD) parameters, and organ-specific toxicities with unprecedented predictive fidelity.

The key directions of this technology are:

  1. Microfluidic Device Microfabrication & Interfacing in Intact Patient-Tumor Ex-Vivo Drug Testing: Precision soft lithography and injection molding of biocompatible, low-sorption cyclic olefin polymer chips supporting dual microfluidic channels separated by porous ECM-coated membranes.
  2. Patient-Derived Multi-Cellular Spheroid & Organoid Biobanking: Standardizing the expansion of patient-derived organoid (PDO) biobanks with defined genetic lineages, preserving patient-specific drug response profiles.
  3. Multi-Organ Microphysiological Vascular Coupling: Interconnecting multiple organ compartments (e.g., gut-liver-kidney) via common recirculating endothelialized vascular channels to model systemic drug metabolism and multi-organ toxicity.
  4. High-Content Automated Phenotypic Screening: Automated confocal 3D image acquisition with machine-learning segmentation to evaluate organoid morphology, lumen integrity, and apoptosis kinetics at high throughput.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Human iPSC / Primary Cell Isolation & Sourcing│
│  (Patient biopsies, HLA-typed iPSC banks, differentiation)
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Chip Microfabrication & Membrane Functionalization│
│  (Cyclic olefin injection molding, ECM protein coating)│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: 3D Micro-Seeding & Air-Liquid / Fluidic Flow  │
│  (Co-culture seeding, programmable micro-perfusion)    │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: In-Line Barrier Integrity & Multi-Organ Run   │
│  (Real-time TEER sensing, cyclic vacuum mechanical stretch)
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Automated High-Content Imaging & Multi-Omics  │
│  (Confocal 3D segmentation, secretome mass spectrometry)
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Cell Sourcing & Stem Cell DifferentiationDerivation, banking, and lineage-specific differentiation of human iPSCs or primary tissue progenitor cells.In: Cryopreserved stem cells, differentiation media, ECM.
Out: High-purity specialized organotypic target cell populations.
Microfluidic Chip Fabrication & Surface ActivationPrecision manufacturing of microchannel cartridges and covalent surface functionalization with laminin or collagen.In: COC/PDMS polymers, porous polyester membranes, ECM.
Out: Surface-modified, sterile microfluidic chip assemblies.
Cell Seeding & Co-Culture Micro-PerfusionCompartmentalized introduction of parenchymal, stromal, and vascular endothelial cells followed by flow initiation.In: Differentiated cells, hydrogel matrix, microfluidic pump.
Out: Vascularized 3D tissue architectures within chip channels.
Dynamic Maturation & In-Line Barrier SensingContinuous fluidic perfusion, cyclic mechanical deformation, and continuous TEER electrical barrier monitoring.In: Recirculating cell culture media, micro-pumps, TEER electrodes.
Out: Physiologically matured organ-on-chip test specimens (>500 Ohm*cm2).
Pharmacological Profiling & Data GenerationExposure to drug candidates, dynamic metabolite sampling, 3D confocal fluorescence imaging, and bioinformatic scoring.In: Test compounds, analytical reagents, HCS automated microscope.
Out: Validated human-predictive efficacy and toxicological dossier.

Cross-cutting technologies of the sector:

  • Transepithelial Electrical Resistance (TEER) Monitoring: In-line impedance micro-electrodes providing continuous non-invasive measurement of epithelial/endothelial tight junction integrity.
  • Automated 3D High-Content Confocal Metrology: Volumetric optical reconstruction quantifying lumen formation, cell viability, and cellular heterogeneity across microfluidic arrays.

2 · What it replaces 3 · matched by industry

3 · How to implement 4 steps

  1. 1
    Precision mechanical tissue precision vibratome slicing
    Sectioning fresh biopsy cores into 200-300 µm viable intact organotypic slices without enzymatic digestion.
  2. 2
    Dynamic micro-perfusion chamber incubation
    Positioning tumor fragments in multi-well microfluidic chips continuously replenished with oxygenated nutrient media.
  3. 3
    Robotic combinatorial drug dispensing
    Administering therapeutic drug panels across parallel chambers at clinically achievable peak plasma concentrations.
  4. 4
    Confocal single-cell apoptosis profiling
    Quantifying live-dead fluorescent probes and cleaved caspase-3 in deep tissue layers to calculate personalized tumor response scores.

4 · Who delivers

Matched suppliers (matched automatically)

Altos LabsUnited StatesResearch / RTOactive
AstraZenecaUnited KingdomProduceractive
China Resources PharmaceuticalHong KongProduceractive
MeijiJapanResearch / RTOactive
HLB Genex (ex-GenoFocus)South KoreaProduceractive
MindrayChinaProduceractive
Scholar RockUnited StatesProduceractive
Eggoz NutritionIndiaProduceractive
FreseniusGermanyProduceractive
Isomorphic LabsUnited KingdomResearch / RTOactive
Kirin HoldingsJapanProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Miltenyi Biotec🇩🇪 GermanyCliniMACS Prodigy Automated ProcessingStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Lonza Cell & Gene🇨🇭 SwitzerlandCocoon Closed Manufacturing PlatformStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Cytiva🇺🇸 United StatesXuri Cell Expansion Bioreactors & SefiaStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
WuXi Advanced Therapies🇨🇳 ChinaViral Vector Testing & Analytical DevelopmentStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Sartorius Stedim Biotech🇩🇪 GermanyAmbr Bioreactors & Process PAT SystemsStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved
Thermo Fisher Scientific🇺🇸 United StatesGibco CTS Cell Therapy MediaStandardized cGMP ATMP bioprocess module and validated analytical release assay suite.Commercial / Approved

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

FDA Modernization Act 2.0, NIH Microphysiological Systems consortia#

  • FDA Modernization Act 2.0 Implementation: Statutory authorization enabling organ-on-chip and human organoid data for Intact Patient-Tumor Ex-Vivo Drug Testing to replace or complement animal safety testing in IND submissions.
  • NCATS Microphysiological Systems Program: Multi-center NIH partnerships standardizing MPS reproducibility, inter-laboratory qualification, and clinical translation.
  • Big Pharma Testing Consortia: Direct integration of multi-organ MPS platforms into early drug discovery ADME-Tox screening cascades across major US biopharma.

European Union

EUROoCS consortia, 3Rs animal replacement frameworks, EMA guidelines#

  • European Organ-on-Chip Society (EUROoCS): Harmonizing technical interfaces, open-source standards, and reproducibility criteria across European academic and CDMO centers.
  • EU 3Rs Directive (2010/63/EU): Strong regulatory pressure to reduce, refine, and replace animal experimentation driving proactive adoption of human-relevant MPS systems.
  • Horizon Europe Collaborative Frameworks: Multi-national consortia developing disease-specific organ-on-chip platforms for neurodegenerative and immune-mediated diseases.

China

National high-tech R&D programs, NMPA organoid standards, regional chips#

  • National Key R&D Program for Organoids & MPS: Direct state funding fostering domestic chips and organoid biobanks under 患者原代完整肿瘤微碎片离体药敏高通量快速筛查技术.
  • NMPA Regulatory Science Initiative: Formulating technical standards and validation guidelines for organoid drug sensitivity testing in precision oncology.
  • Microfluidic Manufacturing Industrial Clusters: High-density biomedical manufacturing ecosystems across Shenzhen, Suzhou, and Shanghai producing medical-grade COC microchips.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Microfluidic Fluidic Architecture in Intact Patient-Tumor Ex-Vivo Drug Testing:
    • Cyclic olefin copolymer (COC) substrates with low non-specific small-molecule drug adsorption.
    • Porous track-etched membrane interfaces supporting physiologically relevant fluid shear stress (0.2–2 dyn/cm2).
  2. Organotypic Cellular Assembly:
    • Human iPSC-derived multicellular co-cultures containing parenchymal cells, primary microvascular endothelial cells, and tissue-resident macrophages.
    • Synthetic hydrogel extracellular matrices with tunable stiffness and matrix metalloproteinase (MMP) cleavage motifs.
  3. Integrated Analytical Sensing Suite:
    • Embedded thin-film gold microelectrodes delivering automated TEER resistance logging.
    • Microfluidic effluent fraction collection coupled directly to micro-flow LC-MS/MS for real-time drug metabolite profiling.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22